Company intelligence / Profile preview

Salt

Cambridge, Massachusetts, United States

Ownership: Private
Development stage: Other

Overview

Salt Bio is a biotechnology company focused on developing a novel class of small molecule therapeutics targeting Salt-Inducible Kinases (SIKs). The company's platform leverages the role of SIKs as master regulators of gene expression in immune cells and tumor microenvironments to treat autoimmune and inflammatory diseases as well as cancer. By selectively inhibiting specific SIK isoforms, Salt Bio aims to reprogram cellular responses to restore immune balance or enhance anti-tumor immunity. The company is currently advancing a pipeline of proprietary SIK inhibitors through pre-clinical development.

Therapeutic areas: OncologyImmunology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Salt.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Salt.

Explore the full profile